BioSpace News Archive

Pixee Medical, a pioneer in digitally augmented surgery technology, announces that Dr Antonia Chen performed the first Knee+ surgeries in the USA at the Brigham and Women’s Hospital in Boston.

Biolinq Incorporated, a medical device company developing a continuous glucose sensor with a novel integrated display on its wearable device, has announced the closing of a $100 million Series B financing round led by RiverVest Venture Partners.

Immunicom, Inc. recently co-hosted an international oncology meeting with Acibadem Healthcare Group at Acibadem University Hospital in Istanbul, Turkey.

Pinnacle Clinical Research, PLLC is enrolling participants into RESPONSE, a global phase 3 clinical research study evaluating the safety and efficacy of seladelpar, an investigational drug for people already diagnosed with PBC who have been using ursodeoxycholic acid but have not achieved the recommended treatment goal or cannot tolerate UDCA.

Agile Therapeutics, Inc., a women’s healthcare company, reported financial results for the three months ended September 30, 2021 and provided a corporate update.

Recro Pharma, Inc., a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, announced that the company will release financial results for the third quarter 2021 after the market close on Tuesday, November 9, 2021.

Amedisys, Inc. reported its financial results for the three and nine-month periods ended September 30, 2021.

Inspire Medical Systems, Inc., a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, reported financial results for the quarter ended September 30, 2021.

Turning Point Therapeutics, Inc., a precision oncology company developing next-generation therapies that target genetic drivers of cancer, announced that it will report third quarter financial results following the close of U.S. financial markets on November 9.

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, reported its financial results for the third quarter 2021.